Teleflex Incorporated (TFX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Teleflex Incorporated.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 136.70 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -10.6% failed
- More than 10% revenue growth is expected for the coming year 4.9% failed
- Share count grows by less than 3% a year -1.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -22.3% failed
- Gross margin at 40% or higher and without meaningful erosion 56.2% passed
- Goodwill from acquisitions does not grow faster than revenue 33.2% failed
- Net debt below twice EBITDA 7.7 x EBITDA failed
- Operating cash flow covers the profits of the last three years 1,967 m passed
- Return on capital at 15% or higher, or up versus two years ago 4.1% failed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 8.7% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6.67 | 6.40 – 8.05 | 2,287 | -4.5% | 13 |
| 12/31/2027 | 10.58 | 8.99 – 11.53 | 2,397 | 58.7% | 13 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.28 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -2.95 | -548.10 | 795 | 2.80 | -17.20 | 203 | 170 |
| 2025: Q1 | 2.07 | 541.20 | 701 | -5.00 | 13.60 | 73 | 43 |
| 2025: Q2 | 2.67 | 57.90 | 781 | 4.20 | 15.70 | 8 | -27 |
| 2025: Q3 | -9.24 | -491.50 | 913 | 19.40 | -44.80 | 108 | 78 |
| 2025: Q4 | -16.15 | – | 569 | -28.50 | -125.50 | 152 | 152 |
| 2026: Q1 | -0.18 | -108.90 | 548 | -21.80 | -1.50 | 47 | 47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,868 | 319 | 237 | 4.98 | 408 | 2,139 | 3,891 |
| 2017 | 2,146 | 372 | 153 | 3.27 | 420 | 2,431 | 6,181 |
| 2018 | 2,448 | 322 | 201 | 4.29 | 437 | 2,540 | 6,278 |
| 2019 | 2,595 | 427 | 461 | 9.80 | 440 | 2,979 | 6,310 |
| 2020 | 2,537 | 423 | 335 | 7.09 | 436 | 3,336 | 7,153 |
| 2021 | 2,810 | 628 | 485 | 10.23 | 651 | 3,755 | 6,872 |
| 2022 | 2,791 | 500 | 363 | 7.68 | 342 | 4,022 | 6,928 |
| 2023 | 2,974 | 506 | 356 | 7.53 | 511 | 4,441 | 7,533 |
| 2024 | 3,047 | 151 | 70 | 1.48 | 636 | 4,278 | 7,098 |
| 2025 | 1,993 | 256 | -906 | -20.25 | 341 | 3,125 | 6,947 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Teleflex Incorporated entwirft, entwickelt, fertigt und liefert Einweg-Medizinprodukte für gängige diagnostische und therapeutische Verfahren in der Intensivmedizin und Chirurgie in den USA, Europa, dem Nahen Osten, Afrika, im asiatisch-pazifischen Raum und international. Das Unternehmen bietet…
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 15,500 |
| Headquarters | Wayne, PA |
| Address | 550 East Swedesford Road, 19087-1603 Wayne, United States |
| Phone | 610-225-6800 |
| Website | teleflex.com |
| IPO Date | 18. Feb 1988 |
| ISIN | US8793691069 |
| Stock Split | 2:1 on 06/17/1997 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John R. Deren | Executive VP & CFO | 1968 |
| Daniel V. Logue J.D. | Corporate VP, General Counsel & Secretary | 1974 |
| Cameron P. Hicks | Corporate Vice President of Human Resources & Communications | 1965 |
| Jason Weidman | President, CEO & Director | – |
| Timothy F. Duffy | VP & Chief Information Officer | – |
| Lawrence Soren Keusch | Vice President of Investor Relations & Strategy Development | – |
| Howard Cyr | Corporate VP & Chief Compliance Officer | – |
| Matt Tomkin | Vice President of Corporate Development | – |
| James Ferguson | President & GM of Surgical | – |
| Matthew James | President & GM of Interventional | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.